Revisión por temas de las últimas publicaciones en las que han participado miembros de GETECCU

Archivado en Noticias

INVESTIGACIÓN BÁSICA

1.Identification of Epigenetic Methylation Signatures With Clinical Value in Crohn’s Disease.
Moret-Tatay I., Cerrillo E., Sáez-González E., Hervás D., Iborra M., Sandoval J., Busó E., Tortosa L., Nos P., Beltrán B.
Clin Transl Gastroenterol. 2019 Oct 28. doi: 10.14309/ctg.0000000000000083. [Epub ahead of print] PubMed PMID: 31703025.

2.Immunomodulatory Effect of Gut Microbiota-Derived Bioactive Peptides on Human Immune System from Healthy Controls and Patients with Inflammatory Bowel Disease.
Fernández-Tomé S., Marin A.C., Ortega Moreno L., Baldan-Martin M., Mora-Gutiérrez I., Lanas-Gimeno A., Moreno-Monteagudo J.A., Santander C., Sánchez B., Chaparro M., Gisbert J.P., Bernardo D.
Nutrients. 2019 Oct 31;11(11). pii: E2605. doi: 10.3390/nu11112605. PubMed PMID: 31683517.

3.Genetic predictors of long-term response and trough levels of infliximab in crohn’s disease.
Salvador-Martín S., López-Cauce B., Nuñez O., Laserna-Mendieta E.J., García M.I., Lobato E., Abarca-Zabalía J., Sanjurjo-Saez M., Lucendo A.J., Marín-Jiménez I., Menchén L.A., López-Fernández L.A.
Pharmacol Res. 2019 Nov;149:104478. doi: 10.1016/j.phrs.2019.104478. Epub 2019 Oct 9. Review. PubMed PMID: 31605784.

4.Functional rare variants influence the clinical response to anti-TNF therapy in Crohn’s disease.
Chaparro M., Aterido A., Guerra I., Iborra M., Cabriada J.L., Bujanda L., Taxonera C., García-Sánchez V., Marín-Jiménez I., Barreiro-de Acosta M., Vera I., Martín-Arranz M.D., Hernández-Breijo B., Mesonero F., Sempere L., Gomollón F., Hinojosa J., Bermejo F.,Beltrán B., Rodríguez-Pescador A., Banales J.M., Olivares D., Aguilar-Melero P., Menchén L., Ferreiro-Iglesias R., Blazquez Gómez I., Benitez García B., Guijarro L.G., Marin A.C., Bernardo D., Marsal S., Julia A., Gisbert JP.
Therap Adv Gastroenterol. 2019 Sep 25;12:1756284819867848. doi: 10.1177/1756284819867848. eCollection 2019. PubMed PMID: 31598133; PubMed Central PMCID: PMC6764039.

5.Autophagy Stimulation as a Potential Strategy Against Intestinal Fibrosis.
Cosin-Roger J., Canet F., Macias-Ceja D.C., Gisbert-Ferrándiz L., Ortiz-Masiá D., Esplugues J.V., Alós R., Navarro F., Barrachina M.D., Calatayud S.
Cells. 2019 Sep 13;8(9). pii: E1078. doi: 10.3390/cells8091078. PubMed PMID: 31540207; PubMed Central PMCID: PMC6770118.

6.Intestinal Inflammation Modulates the Epithelial Response to Butyrate in Patients With Inflammatory Bowel Disease.
Ferrer-Picón E., Dotti I., Corraliza A.M., Mayorgas A., Esteller M., Perales J.C., Ricart E., Masamunt M.C., Carrasco A., Tristán E., Esteve M., Salas A.
Inflamm Bowel Dis. 2019 Jun 18. pii: izz119. doi: 10.1093/ibd/izz119. [Epub ahead of print] PubMed PMID: 31211831.

7.Genetic association between CD96 locus and immunogenicity to anti-TNF therapy in Crohn’s  disease.
Aterido A., Palau N., Domènech E., Nos Mateu P., Gutiérrez A., Gomollón F., Mendoza J.L., Garcia-Planella E., Barreiro-de Acosta M., Muñoz F., Vera M., Saro C., Esteve M., Andreu M., Chaparro M., Panés J., García-Sánchez V., López-Lasanta M., Pluma A., Codó L., García-Montero A., Manyé J., Gisbert J.P., Marsal S., Julià A.
Pharmacogenomics J. 2019 Dec;19(6):547-555. doi: 10.1038/s41397-019-0090-4. Epub 2019 May 2. PubMed PMID: 31043678.

8.Actual Anti-TNF Trough Levels Relate to Serum IL-10 in Drug-Responding Patients With Crohn’s Disease.
Zapater P., Almenara S., Gutiérrez A., Sempere L., García M., Laveda R., Martínez A., Scharl M., Cameo J.I., Linares R., González-Navajas J.M., Wiest R., Rogler G., Francés R.
Inflamm Bowel Dis. 2019 Jul 17;25(8):1357-1366. doi: 10.1093/ibd/izz012. PubMed PMID: 30776076.

EPIDEMIOLOGÍA

1.Young age and tobacco use are predictors of lower medication adherence in inflammatory bowel disease.
Bruna-Barranco I., Lué A., Gargallo-Puyuelo C.J., Arroyo M.T., Alfambra E., Montero J., Gomollón F.
Eur J Gastroenterol Hepatol. 2019 Aug;31(8):948-953. doi: 10.1097/MEG.0000000000001436. PubMed PMID: 31107739.

2.Bases for the Adequate Development of Nutritional Recommendations for Patients with Inflammatory Bowel Disease.
Sáez-González E., Mateos B., López-Muñoz P., Iborra M., Moret I., Nos P., Beltrán B.
Nutrients. 2019 May 12;11(5). pii: E1062. doi: 10.3390/nu11051062. PubMed PMID: 31083616; PubMed Central PMCID: PMC6567870.

3.Influence of Vitamin D Deficiency on Inflammatory Markers and Clinical Disease Activity in IBD Patients.
López-Muñoz P., Beltrán B., Sáez-González E., Alba A., Nos P., Iborra M.
Nutrients. 2019 May 11;11(5). pii: E1059. doi: 10.3390/nu11051059. PubMed PMID: 31083541; PubMed Central PMCID: PMC6567866.

4.Impact and risk factors of non-adherence to 5-aminosalicylates in quiescent ulcerative colitis evaluated by an electronic management system.
Ballester M.P., Marti-Aguado D., Fullana M., Bosca-Watts M.M., Tosca J., Romero E., Sanchez A., Navarro-Cortes P., Anton R., Mora F., Minguez M.
Int J Colorectal Dis. 2019 Jun;34(6):1053-1059. doi: 10.1007/s00384-019-03271-9. Epub 2019 Apr 8. PubMed
PMID: 30963247.

5.Prevalence and Factors Associated With Fatigue in Patients With Inflammatory Bowel Disease: A Multicentre Study.
Chavarría C., Casanova M.J., Chaparro M., Barreiro-de Acosta M., Ezquiaga E., Bujanda L., Rivero M., Argüelles-Arias F., Martín-Arranz M.D., Martínez-Montiel M.P., Valls M., Ferreiro-Iglesias R., Llaó J., Moraleja-Yudego I., Casellas F., Antolín-Melero B., Cortés X., Plaza R., Pineda J.R., Navarro-Llavat M., García-López S., Robledo-Andrés P., Marín-Jiménez I., García-Sánchez V., Merino O., Algaba A., Arribas-López M.R., Banales J.M., Castro B., Castro-Laria L., Honrubia R., Almela P., Gisbert J.P.
J Crohns Colitis. 2019 Aug 14;13(8):996-1002. doi: 10.1093/ecco-jcc/jjz024. PubMed PMID: 30721954.

6.Characteristics of inflammatory bowel disease in patients of Roma/Gypsy ethnicity. A case-control study.
Cabré E., Mañosa M., Marín I., Martín-Mateos R., Iglesias-Flores E.,
Barreiro-de-Acosta M., Nos P., Busquets D., Menchén L.A., López-Sanromán A., Domènech E.
Dig Liver Dis. 2019 May;51(5):669-674. doi: 10.1016/j.dld.2018.12.004. Epub 2018 Dec 19. PubMed PMID: 30606697.

DIAGNÓSTICO

1.Comparison of small-bowel colon capsule endoscopy system to conventional colonoscopy for the evaluation of ulcerative colitis activity.
Adler S.N., González Lama Y., Matallana Royo V., Suárez Ferrer C., Schwartz A., Bar-Gil Shitrit A.
Endosc Int Open. 2019 Oct;7(10):E1253-E1261. doi: 10.1055/a-0982-2786. Epub 2019 Oct 1. PubMed PMID: 31579707; PubMed Central
PMCID: PMC6773590.

2.Metabolic bone disease in patients diagnosed with inflammatory bowel disease from Spain.
Miranda-Bautista J., Verdejo C., Díaz-Redondo A., Bretón I., Bellón J.M., Pérez-Valderas M.D., Caballero-Marcos A., de Dios-Lascuevas M., González-Río E., García-Sánchez C., Marín-Jiménez I., Bañares R., Menchén L.
Therap Adv Gastroenterol. 2019 Jul 31;12:1756284819862152. doi: 10.1177/1756284819862152. eCollection 2019. PubMed PMID: 31391867; PubMed Central PMCID: PMC6669853.

3.The relationship between inflammatory bowel disease and Parkinson’s disease: true or fiction?
Carmona-Abellan M., Rodríguez-Lago I., Cabriada J.L., Gómez-Esteban J.C.
Scand J Gastroenterol. 2019 Jul;54(7):886-889. doi: 10.1080/00365521.2019.1641739. Epub 2019 Jul 17. PubMed PMID: 31314610.

4.Predictors of Infliximab trough concentrations in inflammatory bowel disease patients using a repeated measures design.
Santacana E., Rodríguez-Alonso L., Padullés A., Guardiola J., Bas J., Rodríguez-Moranta F., Serra K., Morandeira F., Colom H., Padullés N.
Ther Drug Monit. 2019 Jul 3. doi: 10.1097/FTD.0000000000000669. [Epub ahead of print] PubMed PMID: 31283556.

5.Perioperative management and early complications after intestinal resection with ileocolonic anastomosis in Crohn’s disease: analysis from the PRACTICROHN study.
Gutiérrez A., Rivero M., Martín-Arranz M.D., García Sánchez V., Castro M., Barrio J., de Francisco R., Barreiro-de Acosta M., Juliá B., Cea-Calvo L., Romero C., Borruel Sainz N., Domènech E.
Gastroenterol Rep (Oxf). 2019 Jun;7(3):168-175. doi: 10.1093/gastro/goz010. Epub 2019 Apr 19. PubMed PMID: 31217980; PubMed Central PMCID: PMC6573802.

6.Endoscopic follow-up and therapeutic attitude after ileocolonic resection in a nationwide Spanish cohort of Crohn’s disease patients: the Practicrohn study.
Barreiro-De Acosta M., Domènech E., Martín Arranz M.D., García Sánchez V., Gutiérrez Casbas A., Chaparro M., Alcain G., Iborra M., Taxonera C., Rodriguez-Lago I., Menchén L., Khorrami S., Romero C., Cea-Calvo L., Juliá B.
Expert Rev Gastroenterol Hepatol. 2019 Aug;13(8):807-813. doi: 10.1080/17474124.2019.1626717. Epub 2019 Jun 17. PubMed PMID: 31203691.

7.Even non-experts identify non-dysplastic lesions in inflammatory bowel disease via chromoendoscopy: results of a screening program in real-life.
Aladrén B.S., González-Lama Y., García-Alvarado M., Sierra M., Barrio J.A., Vicente V.P., Hernández L., Velayos B., Garcia L.A., Relea L., Suarez P., Atienza R., Vásquez M., Fernández-Salazar L., Muñoz F; GEICYL (group of inflammatory bowel disease of Castilla y León).
Endosc Int Open. 2019 Jun;7(6): E743-E750. doi: 10.1055/a-0839-4514. Epub 2019 May 17. PubMed PMID: 31157291; PubMed Central PMCID: PMC6524993.

8.Development and Validation of a Simplified Magnetic Resonance Index of Activity for Crohn’s Disease.
Ordás I., Rimola J., Alfaro I., Rodríguez S., Castro-Poceiro J., Ramírez-Morros A., Gallego M., Giner À., Barastegui R., Fernández-Clotet A., Masamunt M., Ricart E., Panés J.
Gastroenterology. 2019 Aug;157(2):432-439.e1. doi: 10.1053/j.gastro.2019.03.051. Epub 2019 Apr 3. PubMed PMID: 30953614.

9.Clinical Impact of Sonographic Transmural Healing After Anti-TNF Antibody Treatment in Patients with Crohn’s Disease.
Paredes J.M., Moreno N., Latorre P., Ripollés T., Martinez M.J., Vizuete J., Moreno-Osset E.
Dig Dis Sci. 2019 Sep;64(9):2600-2606. doi: 10.1007/s10620-019-05567-w. Epub 2019 Mar 14. PubMed PMID: 30874986.

10.Nivolumab-induced immune-mediated colitis: an ulcerative colitis look-alike-report of new cases and review of the literature.
Cañete F., Mañosa M., Lobatón T., Mesonero F., Rodríguez-Lago I., Cabré E.,
Cabriada J.L., López-Sanromán A., Domènech E.
Int J Colorectal Dis. 2019 May;34(5):861-865. doi: 10.1007/s00384-019-03268-4. Epub 2019 Mar 3. Review. PubMed PMID: 30826963.

11.Faecal calprotectin in inflammatory bowel diseases: a review focused on meta-analyses and routine usage limitations.
Laserna-Mendieta E.J., Lucendo AJ.
Clin Chem Lab Med. 2019 Aug 27;57(9):1295-1307. doi: 10.1515/cclm-2018-1063. Review. PubMed PMID: 30785706.

12.Paradoxical Arthritis in Inflammatory Bowel Diasease Patients on Ustekinumab Treatment.
García García M.J., Rivero Tirado M., Callizo M.E.P.
Inflamm Bowel Dis. 2019 Jun 18;25(7): e89. doi: 10.1093/ibd/izz019. PubMed PMID: 30776300.

13.Short Disease Duration Does Not Always Indicate Early Crohn’s Disease.
Rodríguez-Lago I., Barreiro-de Acosta M.
Clin Gastroenterol Hepatol. 2019 Jul;17(8):1646. doi: 10.1016/j.cgh.2019.01.017. Epub 2019 Jan 18. PubMed PMID: 30664948.

14.Intravenous Contrast-Enhanced Ultrasound for Assessing and Grading Postoperative Recurrence of Crohn’s Disease.
Martínez M.J., Ripollés T., Paredes J.M., Moreno-Osset E., Pazos J.M., Blanc E.
Dig Dis Sci. 2019 Jun;64(6):1640-1650. doi: 10.1007/s10620-018-5432-6. Epub 2019 Jan 2. PubMed PMID: 30604372.

OPCIONES TERAPÉUTICAS

1.Long-term follow-up of patients treated with aminosalicylates for ulcerative colitis: Predictive factors of response: An observational case-control study.
Marti-Aguado D., Ballester M.P., Tosca J., Bosca-Watts M.M., Navarro P., Anton R., Pascual I., Mora F., Minguez M.
United European Gastroenterol J. 2019 Oct;7(8):1042-1050. doi: 10.1177/2050640619854277. Epub 2019 May 29. PubMed PMID: 31662861; PubMed Central PMCID: PMC6794696.

2.Are there reliable predictive factors of nonresponse to aminosalicylates in patients with ulcerative colitis?
Gisbert J.P., Chaparro M.
United European Gastroenterol J. 2019 Oct;7(8):997-998. doi: 10.1177/2050640619861891. Epub 2019 Sep 27. PubMed PMID: 31662857; PubMed Central PMCID: PMC6794694.

3.The role of immunomodulators and biologics in the medical management of stricturing Crohn’s disease.
Rodríguez-Lago I., Gisbert J.P.
J Crohns Colitis. 2019 Sep 21. pii: jjz158. doi: 10.1093/ecco-jcc/jjz158. [Epub ahead of print] PubMed PMID: 31541235.

4.The combination of granulocyte-monocyte apheresis and vedolizumab: A new treatment option for ulcerative colitis?
Rodríguez-Lago I., Benítez J.M., Sempere L., Sáez-González E., Barreiro-de Acosta M., de Zárate J.O., Cabriada J.L.
J Clin Apher. 2019 Dec;34(6):680-685. doi: 10.1002/jca.21746. Epub 2019 Sep 13. PubMed PMID: 31518013.

5.Immunosuppression for inflammatory bowel disease does not influence Epstein-Barr viral load in the short-term.
Rodríguez-Lago I., Merino O., López de Goicoechea M.J., Aranzamendi M., Zubiaurre L., Muro N., Ortiz de Zárate J., Cilla G., Cabriada J.L.
Gastroenterol Hepatol. 2019 Nov;42(9):542-547. doi: 10.1016/j.gastrohep.2019.03.016. Epub 2019 Aug 8. English, Spanish. PubMed PMID: 31402179.

6.Long-term follow up after switching from original infliximab to an infliximab biosimilar: real-world data.
Guerra Veloz M.F., Belvis Jiménez M., Valdes Delgado T., Castro Laria L., Maldonado Pérez B., Perea Amarillo R., Merino Bohórquez V., Caunedo Álvarez Á., Vilches Arenas Á., Argüelles-Arias F.
Therap Adv Gastroenterol. 2019 Jun 18;12:1756284819858052. doi: 10.1177/1756284819858052. eCollection 2019. PubMed PMID: 31258621; PubMed Central PMCID: PMC6585238.

7. A Prospective Pilot Randomized Study: Electroacupuncture vs. Sham Procedure for the Treatment of Fatigue in Patients With Quiescent Inflammatory Bowel Disease.
Horta D., Lira A., Sanchez-Lloansi M., Villoria A., Teggiachi M., García-Rojo D., García-Molina S., Figuerola A., Esteve M., Calvet X.
Inflamm Bowel Dis. 2019 May 15. pii: izz091. doi: 10.1093/ibd/izz091. [Epub ahead of print] PubMed PMID: 31091322.

8.Effectiveness and Safety of the Switch from Remicade® to CT-P13 in Patients with Inflammatory Bowel Disease.
Chaparro M., Garre A., Guerra Veloz M.F., Vázquez Morón J.M., De Castro M.L., Leo E., Rodriguez E., Carbajo A.Y., Riestra S., Jiménez I., Calvet X., Bujanda L., Rivero M., Gomollón F., Benítez J.M., Bermejo F., Alcaide N., Gutiérrez A., Mañosa M., Iborra M., Lorente R., Rojas-Feria M., Barreiro-de Acosta M., Kolle L., Van Domselaar M., Amo V., Argüelles F., Ramírez E., Morell A., Bernardo D., Gisbert JP.
J Crohns Colitis. 2019 Oct 28;13(11):1380-1386. doi: 10.1093/ecco-jcc/jjz070. PubMed PMID: 30976785.

9.Early dose optimization of golimumab induces late response and long-term clinical benefit in moderately to severely active ulcerative colitis.
Taxonera C., Iborra M., Bosca-Watts M.M., Rubio S., Nantes Ó., Higuera R., Bertoletti F., Martínez-Montiel P., Sierra-Ausin M., Manceñido N., Lázaro Pérez-Calle J., Algaba A., Olivares D., Alba C.
Curr Med Res Opin. 2019 Jul;35(7):1297-1304. doi: 10.1080/03007995.2019.1579557. Epub 2019 Mar 13. PubMed PMID:30722703.

10.Regain of Response to Adalimumab in a Steroid-Dependent Pediatric Patient With Ulcerative Colitis After Undergoing Selective Granulocyte and Monocyte Apheresis.
Velasco Rodríguez-Belvís M., Viada Bris J.F., Palomino Pérez L., Muñoz Codoceo R.A.
Inflamm Bowel Dis. 2019 Jun 18;25(7):e82-e83. doi: 10.1093/ibd/izy404. PubMed PMID: 30698787.

11.Relevant Infections in Inflammatory Bowel Disease, and Their Relationship With Immunosuppressive Therapy and Their Effects on Disease Mortality.
Zabana Y., Rodríguez L., Lobatón T., Gordillo J., Montserrat A., Mena R., Beltrán B., Dotti M., Benitez O., Guardiola J., Domènech E., Garcia-Planella E., Calvet X., Piqueras M., Aceituno M., Fernández-Bañares F., Esteve M.
J Crohns Colitis. 2019 Jul 25;13(7):828-837. doi: 10.1093/ecco-jcc/jjz013. PubMed PMID: 30668662.

12.Withdrawal of Azathioprine in Inflammatory Bowel Disease Patients Who Sustain Remission: New Risk Factors for Relapse.
Iborra M., Herreras J., Boscá-Watts M.M., Cortés X., Trejo G., Cerrillo E., Hervás D., Mínguez M., Beltrán B., Nos P.
Dig Dis Sci. 2019 Jun;64(6):1612-1621. doi: 10.1007/s10620-018-5429-1. Epub 2019 Jan 2. PubMed PMID: 30604371.

IMPACTO CVRS. PERCEPCIONES PACIENTES

1.Improving Quality of Care in Inflammatory Bowel Disease Through Patients’ Eyes: IQCARO Project.
Calvet X., Saldaña R., Carpio D., Mínguez M., Vera I., Juliá B., Marín L., Casellas F.
Inflamm Bowel Dis. 2019 Oct 21. pii: izz126. doi:10.1093/ibd/izz126. [Epub ahead of print] PubMed PMID: 31634907.

2.Association between non-adherence behaviors, patients’ experience with healthcare and beliefs in medications: a survey of patients with different chronic conditions.
Cea-Calvo L., Marín-Jiménez I., de Toro J., Fuster-RuizdeApodaca M.J., Fernández G., Sánchez-Vega N., Orozco-Beltrán D.
Curr Med Res Opin. 2019 Oct 15:1-8. doi: 10.1080/03007995.2019.1676539. [Epub ahead of print] PubMed PMID: 31580168.

3.Status of transition care in inflammatory bowel disease in Spain. Different medical perspectives.
Sánchez Sánchez C., Tolín Hernani M.D.M., Álvarez Calatayud G., Miranda Cid M.D.C., Navas López V.M., Marín Jiménez I., Menchen L.A., García Fernández P., Merino Sánchez-Cañete A.
Rev Esp Enferm Dig. 2019 Nov;111(11):833-838. doi: 10.17235/reed.2019.6310/2019. PubMed PMID: 31566409.

4.Telemonitoring of Crohn’s Disease and Ulcerative Colitis (TECCU): Cost-Effectiveness Analysis.
Del Hoyo J., Nos P., Bastida G., Faubel R., Muñoz D., Garrido-Marín A., Valero-Pérez E., Bejar-Serrano S., Aguas M.
J Med Internet Res. 2019 Sep 13;21(9): e15505. doi: 10.2196/15505. PubMed PMID: 31538948; PubMed Central PMCID: PMC6754696.

5.Impact of pain associated with the subcutaneous administration of adalimumab.
Gely C., Marín L., Gordillo J., Mañosa M., Bertoletti F., Cañete F., González-Muñoza C., Calafat M., Domènech E., Garcia-Planella E.
Gastroenterol Hepatol. 2019 Sep 3. pii: S0210-5705(19)30175-X. doi: 10.1016/j.gastrohep.2019.06.008. [Epub ahead of print] English, Spanish. PubMed
PMID: 31492425.

6.Is there any alternative to science? Complementary and alternative therapies for inflammatory bowel diseases.
Gomollón F.
Lancet Gastroenterol Hepatol. 2019 Sep;4(9):664-666. doi: 10.1016/S2468-1253(19)30180-3. PubMed PMID: 31387728.

7.Development and validation of the QUECOMIICAT questionnaire: a tool to assess disease-related knowledge in patients with inflammatory bowel disease.
Casellas F., Navarro E., Amil P., Barber C., Marín L., Guardiola J., Espín E., Sainz E., Aldeguer X., Gallego M., Murciano F., García-Planella E., Martín-de-Carpi J., Mendive J.M., González-Mestre A.
Rev Esp Enferm Dig. 2019 Aug;111(8):586-592. doi: 10.17235/reed.2019.6298/2019. PubMed PMID: 31317762.

8.Healthcare Experience and their Relationship with Demographic, Disease and Healthcare-Related Variables: A Cross-Sectional Survey of Patients with Chronic Diseases Using the IEXPAC Scale.
Orozco-Beltrán D., de Toro J., Galindo M.J., Marín-Jiménez I., Casellas F., Fuster-RuizdeApodaca M.J., García-Vivar M.L., Hormigo-Pozo A., Guilabert M., Sánchez-Vega N., Fernández G., Cea-Calvo L.
Patient. 2019 Jun;12(3):307-317. doi: 10.1007/s40271-018-0345-1. PubMed PMID: 30430456; PubMed Central PMCID: PMC6525115.

PEDIATRÍA

1.Vaccinations and Immunization Status in Pediatric Inflammatory Bowel Disease: A Multicenter Study From the Pediatric IBD Porto Group of the ESPGHAN.
Martinelli M., Giugliano F.P., Strisciuglio C., Urbonas V., Serban D.E., Banaszkiewicz A., Assa A., Hojsak I., Lerchova T., Navas-López V.M., Romano C., Sladek M., Veres G., Aloi M., Kucinskiene R., Miele E.
Inflamm Bowel Dis. 2019 Nov 5. pii: izz264. doi: 10.1093/ibd/izz264. [Epub ahead of print] PubMed PMID: 31689349.

2.Complicated disease and response to initial therapy predicts early surgery in paediatric Crohn’s disease: results from the Porto Group GROWTH study.
Levine A., Chanchlani N., Hussey S., Ziv-Baran T., Escher J.C., Amil Dias J., Veres G., Koletzko S., Turner D., Kolho K.L., Paerregaard A., Staiano A., Lionetti P., Nuti F., Sladek M., Shaoul R., Lazowska-Prezeorek I., de Carpi J.M., Sigall Boneh R., Pfeffer Gik T., Cohen-Dolev N., Russell R.K.; Porto Group of ESPGHAN.
J Crohns Colitis. 2019 Jun 3. pii: jjz111. doi: 10.1093/ecco-jcc/jjz111. [Epub ahead of print] PubMed PMID:31162532.

3.Long-term Outcomes of Paediatric Patients Admitted with Acute Severe Colitis – A Multicenter Study from the Paediatric IBD Porto Group of ESPGHAN.
Krauthammer A., Tzivinikos C., Assa A., Miele E., Strisciuglio C., Urlep D., Serban E.D., Singh A., Winter H.S., Russell R.K., Hojsak I., Malham M., Navas-López V.M.,Croft N.M., Lee H.M., Ledder O., Shamasneh I., Hussey S., Huynh H., Wine E., Shah N., Sladek M., de Meij T.G., Romano C., Dipasquale V., Lionetti P., Afzal N.A., Aloi M., Lee K., Martín-de-Carpi J., Yerushalmy-Feler A., Subramanian S., Weiss B., Shouval D.S.
J Crohns Colitis. 2019 May 23. pii: jjz092. doi: 10.1093/ecco-jcc/jjz092. [Epub ahead of print] PubMed PMID: 31120524.

ECCO

1.Interstitial and Granulomatous lung disease in inflammatory bowel disease patients.
Eliadou E., Moleiro J., Ribaldone D.G., Astegiano M., Rothfuss K., Taxonera C., Ghalim F., Carbonnel F., Verstockt B., Festa S., Maia L., Berrozpe A., Zagorowicz E., Savarino E., Ellul P., Vavricka S.R., Calvo M., Koutroubakis I., Hoentjen F., Luis F.S., Callela F., Cañete Pizarro F., Soufleris K., Sonnenberg E., Cavicchi M., Wypych J., Hommel C., Ghiani A., Fiorino G.; ECCO CONFER COMMITTEE.
J CrohnsColitis. 2019 Oct 11. pii: jjz165. doi: 10.1093/ecco-jcc/jjz165. [Epub ahead of print] PubMed PMID: 31602473.

2.European Crohn’s and Colitis Organisation Topical Review on Complementary Medicine and Psychotherapy in Inflammatory Bowel Disease.
Torres J., Ellul P., Langhorst J., Mikocka-Walus A., Barreiro-de Acosta M., Basnayake C., Ding N.J.S., Gilardi D., Katsanos K., Moser G., Opheim R., Palmela C., Pellino G., Van der Marel S., Vavricka S.R.
J Crohns Colitis. 2019 May 27;13(6):673-685e. doi: 10.1093/ecco-jcc/jjz051. PubMed PMID: 30820529.

3.Disease course of inflammatory bowel disease unclassified in a European population-based inception cohort: An Epi-IBD study.
Burisch J., Zammit S.C., Ellul P., Turcan S., Duricova D., Bortlik M., Andersen K.W., Andersen V., Kaimakliotis I.P., Fumery M., Gower-Rousseau C., Girardin G., Valpiani D., Goldis A., Brinar M., Čuković-Čavka S., Oksanen P., Collin P., Barros L., Magro F., Misra R., Arebi N., Eriksson C., Halfvarson J., Kievit H.A.L., Pedersen N., Kjeldsen J., Myers S., Sebastian S., Katsanos K.H., Christodoulou D.K., Midjord J., Nielsen K.R., Kiudelis G., Kupcinskas L., Nikulina I., Belousova E., Schwartz D., Odes S., Salupere R., Carmona A., Pineda J.R., Vegh Z., Lakatos P.L., Langholz E., Munkholm P.; Epi-IBD group.
J Gastroenterol Hepatol. 2019 Jun;34(6):996-1003. doi: 10.1111/jgh.14563. Epub 2019 Jan 21. PubMed PMID: 30562421.

OTROS

1.Young GI Angle: My best career decision.
Löhr M., Malfertheiner P., Peyrin-Biroulet L., Zabana Y.
United European Gastroenterol J. 2019 Oct;7(8):1136-1138. doi: 10.1177/2050640619877602. Epub 2019 Sep 27. PubMed PMID: 31662871; PubMed Central PMCID: PMC6794691.

2.Spontaneous hepatic portal venous gas in a patient with ulcerative colitis. A case report and a review.
Murzi M., Gordillo J., Oblitas E., Soriano G., Pernas J.C., Posso M., Garcia-Planella E.
Gastroenterol Hepatol. 2019 Oct 19. pii: S0210-5705(19)30199-2. doi: 10.1016/j.gastrohep.2019.08.004. [Epub ahead of print] English, Spanish. PubMed PMID: 31640909.

3.Risk factors for locally advanced cancer associated with ulcerative colitis: Results of a retrospective multicentric study in the era of biologics.
Rottoli M., Tanzanu M., Di Candido F., Colombo F., Frontali A., Chandrasinghe P.C., Pellino G., Frasson M., Warusavitarne J., Panis Y., Sampietro G.M., Spinelli A., Poggioli G.
Dig Liver Dis. 2019 Sep 30. pii: S1590-8658(19)30787-X. doi: 10.1016/j.dld.2019.08.024. [Epub ahead of print] PubMed PMID: 31582324.

4.Adalimumab-induced autoimmune hepatitis in a patient with Crohn’s disease.
Miranda-Bautista J., Menchén L.
Gastroenterol Hepatol. 2019 May;42(5): 306-307.doi: 10.1016/j.gastrohep.2018.06.006. Epub 2018 Jul 17. English, Spanish. PubMed PMID:30029925.

archivado en Noticias | publicado el 28 de noviembre de 2019 | última actualización: 28 de noviembre de 2019 13:26
Formación EII
Canal de GETECCU en YouTube
Base de datos ENEIDA
PROYECTOS GETECCU
Base de datos ENEIDA
Formación EII
VIDEOS DESTACADOS

puedes ver todos los vídeos en nuestros canales de video GETECCU en YouTube y G-EducaEII en YouTube

PODCASTS GETECCU

Escucha todos nuestros podcasts GETECCU Podcasts

Nuestros patrocinadores|lea nuestra política de patrocinio